Genitourinary Cancer, Prostate Cancer
Watch Time: 3 mins

Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years

Copy Link
Published Online: Apr 3rd 2023

Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. He also takes a look to the future, discussing developments he hopes to see in early detection, using imaging and artificial intelligence, and hormone combination therapies to reduce, or even eliminate, the use of chemotherapy.


  1. Please summarize the current most significant advances in prostate cancer (00.15)
  2. What advances can we hope for over the next five years? (02:05)

Disclosures: Axel Merseburger has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed as a highlight of EAU23

Access more content on genitourinary cancers here 


Hi my name is Axel Merseburger. I’m Professor of Urology and Chairman of the Department of Urology here in northern Germany at Lübeck University.

Q1. Please summarize the current most significant advances in prostate cancer

The significant advances in prostate cancer are screening from MRI and detection with PSMA PET-CT scans. These are, I think, the most important advances in localized and advanced localized disease going towards metastatic disease.

Treatment intensification is definitely what we have seen throughout the last year, not just in MHSPC where we have seen data from a treatment intensification from doublet therapy in the TITAN trial, for example, or the ARCHES trial and or PEACE trial for triplet therapy in MHSPC. So not only just ADT but combination of docetaxel and hormone therapy as we’ve just saw at ASCO GU 2023 and also at the EAU meeting with updates from those just aforementioned trials. Aside this, we have seen a lot of advances in this year’s presentations on triplet combinations and MCRPC in combination with PARP inhibitors. So a PARP inhibitor was combined with NHT and ADT hormone therapy and this has prolonged the progression-free survival and also a trend towards overall survival benefit.

So I think here we are in the new era of including PARP inhibitors in MCRPC and I think this for me are the most important developments we are discussing at conferences and also in social media platforms and webinars and life discussions. So those for prostate cancer are my most recent developments.

Thank you.

Q2. What advances can we hope for over the next five years?

I think this is the glass ball question here. What are the advances in the field and what do I hope the next five years to have more efficacious treatment, better working treatment with prolonging overall survival, but reduce side effects would be is a goal for all aspects in cancer in dual cancer. And I think we have advances in imaging. We detect cancer in an earlier stage and we have for prostate cancer, for example, hormone combination which prolong life and we hopefully can spare chemotherapy in the future or get it in the sequence at a later stage or maybe even not.

So I think those are some advances. I am looking forward to the field, definitely imaging, definitely artificial intelligence, what we also use in daily clinical life already and I think there will be a lot of advances from imaging, from detection, from artificial intelligence in the field of GU oncology and urology. Thank you.

Subtitles and transcript are autogenerated.

Related Videos In Prostate Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72